(Q36602264)

15 August 2017

1 reference

title

Virus-like particles: passport to immune recognition (English)

1 reference

15 August 2017

0 references

David A Anderson

2

0 references

David A Anderson

object named as

David A Anderson

series ordinal

2

0 references

author name string

Elizabeth V L Grgacic

series ordinal

1

1 reference

15 August 2017

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

40

1 reference

15 August 2017

1

1 reference

15 August 2017

60-65

1 reference

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Different architectures in the assembly of infectious bursal disease virus capsid proteins expressed in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Antibody responses to preS components after immunization of children with low doses of BioHepB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Virus-like particles as HIV-1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

GP120: target for neutralizing HIV-1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Progress towards the development of a HIV-1 gp41-directed vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Vaccines that facilitate antigen entry into dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Ebola and Marburg virus-like particles activate human myeloid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Papillomavirus-like particles induce acute activation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunodeficiency virus exploitation of dendritic cells in the early steps of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Impairment of thymus-dependent responses by murine dendritic cells infected with foot-and-mouth disease virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

HBV core particles as a carrier for B cell/T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Universal influenza A vaccine: optimization of M2-based constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Soluble recombinant influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A "universal" human influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Preventative and therapeutic vaccines for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Oral immunization with hepatitis B surface antigen expressed in transgenic plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Towards the preparative and large-scale precision manufacture of virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Human hepatitis B vaccine from recombinant yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Recombinant vaccines for hepatitis E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Ebola virus-like particles protect from lethal Ebola virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Filovirus-like particles as vaccines and discovery tools

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunogenicity of peptide fusions to hepatitis B virus core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Combinatorial approach to hepadnavirus-like particle vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A plant signal peptide-hepatitis B surface antigen fusion protein with enhanced stability and immunogenicity expressed in plant cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Expression and purification of Dengue virus type 2 envelope protein as a fusion with hepatitis B surface antigen in Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

A protein particle vaccine containing multiple malaria epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

Expression and self-assembly of empty virus-like particles of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

7 January 2021

inferred from DOI database lookup

Hepatitis C virus structural proteins assemble into viruslike particles in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

7 January 2021

inferred from DOI database lookup

Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.07.018

7 January 2021

inferred from DOI database lookup

Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells

1 reference

12 December 2020

Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine

1 reference

12 December 2020

Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant

1 reference

12 December 2020

A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation

1 reference

12 December 2020

Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin

1 reference

12 December 2020

Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg

1 reference

12 December 2020

10.1016/J.YMETH.2006.07.018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16997714